Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

SLE, atherosclerosis and cardiovascular disease.

J Frostegård1

  • 1Department of Medicine, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden. johan.frostegard@medhs.ki.se

Journal of Internal Medicine
|May 25, 2005
PubMed
Summary

Systemic lupus erythematosus (SLE) significantly increases cardiovascular disease (CVD) risk due to inflammation and antiphospholipid antibodies (aPL). Understanding these factors may reveal mechanisms of premature atherosclerosis and guide targeted treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of IgG1 isotype phosphorylcholine antibodies for the treatment of inflammatory cardiovascular diseases.

Journal of internal medicine·2020
Same author

Immunoglobulin G1 Antibodies Against Phosphorylcholine Are Associated With Protection in Systemic Lupus Erythematosus and Atherosclerosis: Potential Underlying Mechanisms.

ACR open rheumatology·2020
Same author

Different subclasses and isotypes of antibodies against phosphorylcholine in haemodialysis patients: association with mortality.

Clinical and experimental immunology·2020
Same author

Phenotypic features of vascular calcification in chronic kidney disease.

Journal of internal medicine·2019
Same author

Autoantibody profiling reveals four protein candidate autoantigens associated with systemic lupus erythematosus.

Lupus·2018
Same author

PCSK9 plays a novel immunological role in oxidized LDL-induced dendritic cell maturation and activation of T cells from human blood and atherosclerotic plaque.

Journal of internal medicine·2018

Area of Science:

  • Immunology
  • Cardiology
  • Rheumatology

Background:

  • Atherosclerosis, a major cause of cardiovascular disease (CVD), is an inflammatory condition.
  • The specific antigens and mechanisms driving immune activation in atherosclerotic plaques remain unclear.
  • Systemic lupus erythematosus (SLE) patients exhibit a markedly elevated risk of CVD.

Purpose of the Study:

  • To explore the relationship between immune reactions and premature atherosclerosis in SLE.
  • To identify risk factors contributing to CVD in SLE patients.
  • To investigate potential differences in SLE-related atherosclerosis compared to general atherosclerosis.

Main Methods:

  • Review of traditional and nontraditional CVD risk factors in SLE.
  • Analysis of the role of inflammation and antiphospholipid antibodies (aPL).

Related Experiment Videos

  • Comparison of SLE-related atherosclerosis with 'normal' atherosclerosis.

    • Main Results:

    • CVD in SLE is associated with dyslipidemia, hypertension, diabetes, smoking, inflammation, aPL, and lipid oxidation.
    • Premature atherosclerosis and atherothrombosis are likely key mechanisms in SLE-related CVD.
    • Inflammation and aPL may increase the rupture-proneness of atherosclerotic lesions in autoimmune diseases.

    Conclusions:

    • SLE patients require close monitoring of traditional and nontraditional CVD risk factors, including aPL.
    • Further research is needed to determine if premature atherosclerosis is a general feature of SLE.
    • Novel therapies targeting inflammation and immune reactions in atherosclerotic lesions are needed.